{"groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"FG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"FG001","title":"TAS x 28 Weeks"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"46"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"No protocol treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"790"},{"groupId":"FG001","numSubjects":"789"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG000","numSubjects":"752"},{"comment":"Subjects with data available for the primary analysis are considered to have completed the study.","groupId":"FG001","numSubjects":"737"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"52"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}